Belite Bio, Inc
BLTE
$149.34
-$2.45-1.61%
NASDAQ
| 09/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | 122.90% | 110.42% | 110.42% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | 48.80% | 35.58% | 35.58% | -- |
| Operating Income | -- | -48.80% | -35.58% | -35.58% | -- |
| Income Before Tax | -- | -35.86% | -26.86% | -26.86% | -- |
| Income Tax Expenses | -- | -33.33% | -50.00% | -50.00% | -- |
| Earnings from Continuing Operations | -- | -35.84% | -26.84% | -26.84% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -35.84% | -26.84% | -26.84% | -- |
| EBIT | -- | -48.80% | -35.58% | -35.58% | -- |
| EBITDA | -- | -48.71% | -35.42% | -35.40% | -- |
| EPS Basic | -- | -10.42% | -2.38% | -2.38% | -- |
| Normalized Basic EPS | -- | -144.65% | 9.24% | -94.76% | -- |
| EPS Diluted | -- | -10.42% | -2.38% | -2.38% | -- |
| Normalized Diluted EPS | -- | -144.65% | 9.24% | -94.76% | -- |
| Average Basic Shares Outstanding | -- | 21.53% | 22.50% | 22.50% | -- |
| Average Diluted Shares Outstanding | -- | 21.53% | 22.50% | 22.50% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |